Liverpool COVID-19 Interactions

No Interaction Expected

Molnupiravir

Simvastatin

Quality of Evidence: Very Low

Summary:

Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Simvastatin is metabolized by CYP3A4. Molnupiravir does not inhibit or induce CYPs and is unlikely to have significant drug-drug interactions with other therapies. Molnupiravir is rapidly metabolized by esterases to a nucleoside metabolite which is phosphorylated to an active triphosphate.

Description:

(See Summary)